This site is intended for U.S. residents only

The first non-surgical treatment for pruritus in PFIC is now also approved for ALGS1,2

MOA
MOA right arrow

Bylvay reduces cholestatic pruritus, potentially by reducing the bile acid pool2

0.0_Home_icon-Dosing.png
Dosing right arrow

Once-daily dose with no need to delay feeding or mealtimes

The first non-surgical treatment for pruritus in PFIC is now also approved for ALGS1,2

MOA

Bylvay reduces cholestatic pruritus, potentially by reducing the bile acid pool2

Dosing

Once-daily dose with no need to delay feeding or mealtimes

ALL RESOURCES

Helpful Resources

View a range of instructional videos and perspectives from patients and healthcare practitioners, or download helpful resources to support patient care and treatment

ALL RESOURCES
ALL RESOURCES
Albireo

IPSEN CARES serves as a central point of contact between patients/ caregivers, healthcare providers, insurance companies and specialty pharmacies. We help patients get access to their prescribed medications with the information and support they need.

LEARN MORE

Get Your Patients Started with Bylvay

IPSEN CARES serves as a central point of contact between patients/caregivers, healthcare providers, insurance companies and specialty pharmacies. We help patients get access to their prescribed medications with the information and support they need.

LEARN MORE
link navigator

Get in touch with a representative who can answer your questions

ALGS=Alagille syndrome; PFIC=progressive familial intrahepatic cholestasis.

References:
  • Bylvay Prescribing Information. Boston, MA: Albireo Pharma, Inc.; 2023.
  • Kamath BM, Stein P, Houwen RHJ, Verkade HJ. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 2020;40(8):1812-1822.